2024年11月16日-22日，全球医药市场共签署了20项资产授权和合作协议。中国市场共达成9项交易，包括6项出海交易、2项引进交易和1项国内交易。
本周中国市场最大的出海交易是橙帆医药授予Avenzo临床前肿瘤资产VBC103的海外权益，首付款5000万美元，总价值8亿美元。本周最大的引进交易由WY Biotech和HCW Biologics达成，首付款700万美元。本周唯一的国内交易是礼新医药与中国生物制药达成的股权投资及多个资产的战略合作。
国际市场上，共签署了11项资产授权和合作协议。最引人注目的一笔交易是Kura Oncology与Kyowa Kirin就前者的临床1/2期资产ziftomenib达成的全球战略合作，首付款3.3亿美元，总价值14.91亿美元。
Between November 16 and 22, a total of 20 licensing and cooperation deals were signed globally. In the China biotech sector, there were six out-licensing deals, two in-licensing deals, and one domestic deal.
The top out-licensing deal involved VelaVigo and Avenzo Therapeutics for the pre-clinical oncology asset VBC103, with a total value of $800 million, including an upfront payment of $50 million. The top in-licensing deal was between HCW Biologics and WY Biotech's, which featured a $7 million upfront payment. The only domestic deal was finalized by LaNova and Sino Biopharmaceutical for multiple assets.
Globally, 11 licensing and cooperation deals were completed during the week. The most significant global deal was between Kura Oncology and Kyowa Kirin for the Phase I/II asset ziftomenib, valued at $1.491 billion, with an upfront payment of $330 million.
2b. Global section
3. M&A Deals
4. Top Deals of the year 2024
雅法资本成立于2013年，作为新型投资和投行咨询机构，致力于中国及海外生物医药项目的投融资、资产跨境交易和资产孵化等。旗下雅法基金联合药企进行资产投资和并购，雅法全球医疗专注于医药产品跨境及国内授权交易。基于雅法在全球广泛的人脉与资源网络，在过去十年成功推进了大量的海外项目进入中国市场并协助多个中国产品完成海外授权。雅法拥有经验丰富的全球交易团队，覆盖美国、日本 、欧洲等全球主要医药创新区域。核心合伙人均为华尔街资深投行人士或具有跨国药企经历，为客户交易提供强力支持。雅法总部位于上海，在美国、欧洲、东南亚等地均设有分部。雅法在生物医药跨境授权及并购业务交易数量连续多年排名第一。
About YAFO Capital
Founded in 2013, YAFO Capital is a Shanghai based boutique investment and advisory firm, with professional team in our China, U.S., EU and SEA offices. Partnering with Pharmaceutical companies, YAFO Fund mainly invests in global assets. YAFO Life Sciences is a leading advisory boutique focused on asset transactions. YAFO has built a strong proven track record and closed dozens of in-licensing and out-licensing transactions with global pharma and biotech companies. Over the past five years, YAFO has been ranked as the No. 1 advisor for China cross border licensing transactions. For more information, please visit www.yafocapital.com
Event Name:
